anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A system and method for providing logistical management support of objects for consumption at one or more localities within a facility that sources the objects from a store. The system includes a server that allows subscribers to access relevant parts of datastore providing data on objects in the store. Devices are used by different subscribers to setup templates defining use of the objects in variety of situations in a dynamically scheduled manner. Applications operate on the devices for a particular subscriber to perform a task associated with using objects in accordance with different templates. Each application progresses the subscriber through functions involving the creation or performance of a procedure using the objects in accordance with a template. Some of the applications track the use of objects in real time and update the server and datastore with status information. The server communicates with an inventory management system to supplement the data with information concerning the availability and whereabouts of all objects specified in the templates. The server communicates with a booking system to determine when a procedure defined by a particular template will occur.
Participants are dyads consisting of an older adult with MCI/mild ADRD and their care partner. Baseline assessment will include a neuropsychological evaluation to confirm cognitive status for the older adult with MCI/mild ADRD, a series of baseline questionnaires, and introduction to the EMA application. Dyads are randomized to either the CAST or HEC conditions. During CAST sessions, dyads view the CAST presentation and complete interoceptive exposures. An interventionist guides dyads through these sessions. During HEC, dyads view the HEC presentation and complete behavior tracking and goal-setting with the guidance of an interventionist. At both intervention sessions, dyads complete questionnaires including post assessments at the end of intervention session two. For the week prior to intervention session one, the week between the two intervention sessions, and the week after intervention session two, dyads complete daily EMAs about emotional and other factors using an application downloaded on a phone or tablet. At 1, 3, and 6-months follow-up assessments, dyads complete follow-up cognitive testing and outcome questionnaires.
For applications and information, a computer-assisted zoom program or other online programs that can provide meetings (Google meet, teams program or WhatsApp video call) will be used. The students in the intervention group will be informed about the function and application of EFT, it will be explained practically, and the application steps will be taken. This stage is planned to take approximately 15 minutes.
BACKGROUND: Patients (20%-50%) with inflammatory bowel disease (IBD) experience chronic abdominal pain during remission. The clinical features of IBD patients with abdominal pain during remission remain poorly characterized. This cross-sectional pilot study aimed to assess patient recruitment, adherence, and feedback to optimize questionnaires for future use and to determine the clinical features that distinguish IBD patients in remission with and without abdominal pain.
METHODS: Online validated questionnaires about disease activity, symptoms, and psychological factors were sent to participants of the UK National Institute for Health and Care Research (NIHR) IBD BioResource, which is a national research platform consisting of re-callable IBD patients designed to expedite research into Crohn's and colitis. Inclusion/exclusion criteria of the IBD BioResource main cohort were applied. Descriptive and inferential statistics were applied to participants in remission. p-values ≤0.01 were considered significant.
KEY RESULTS: A total of 2050 patients were approached; 291 (14.2%) of these agreed to participate. In 35 patients, technical problems, length, and poor understanding of the relevance of some questionnaires affected completion as confirmed by feedback. In total, 244 patients were full responders with 122 (50%) in remission; 33 (27%) of these had chronic abdominal pain. Comparison of those with versus without (n = 89) chronic abdominal pain yielded higher scores in patients with pain for the following: somatization (p < 0.001); gastrointestinal symptoms rating scale score (p = <0.001); highly sensitive person scale (p = 0.007); catastrophizing score (p = 0.010). Trends were observed for azathioprine use (p = 0.021); coping resources inventory health in general (p = 0.046); neuroticism (p = 0.019); and poor sleep (p = 0.03).
CONCLUSIONS & INFERENCES: Differences in symptoms and psychological characteristics exist between IBD patients in remission with and without abdominal pain. Confirmation of findings in larger studies may facilitate development of personalized chronic pain treatments for IBD patients.
The invention relates to a Chinese medicinal tea-substitution brewing potion for treating allergic rhinitis. The Chinese medicinal tea-substitution brewing potion is characterized by being mainly prepared from the following raw medicinal materials in weight part: 2-5 parts of ephedra, 1-3 part(s) of poria, 1-3 part(s) of monkshood, 2-5 parts of astragalus root, 2-5 parts of honeysuckle flower, 1-3 part(s) of licorice and 1-3 part(s) of jujube. The Chinese medicinal tea-substitution brewing potion is prepared by the following steps of: respectively cutting the raw medicinal materials into slices or thin segments and mixing the raw materials. 30-60g of the mixed raw materials is taken as a dose each time, is brewed by using boiled water for 20-40 minutes, then can be drunk, and can be continuously brewed by using the boiled water 5-8 times for drinking, and then, medicine dregs are thrown away. A patient can drink 1-2 dose(s) each day, and the disease can be remarkably or thoroughly treated by drinking for 1-3 dose(s). The Chinese medicinal tea-substitution brewing potion disclosed by the invention has the functions of benefiting defensive qi and strengthening exterior, detoxicating and promoting tissue generation, promoting eruption to relieve itching, and the like, and is used for treating the allergic rhinitis.
Device data is obtained from one or more devices for an individual. The one or more devices include one or more medical monitoring devices. Data is also obtained from one or more exogenous sources, and the data includes current data relating to one or more medical resources. The device data obtained from the one or more devices and the data from the one or more exogenous sources are analyzed using an artificial intelligence agent. Based on the analyzing, one or more recommendations are provided. The one or more recommendations include an indication of a device to use that is different from the one or more devices to obtain different device data for the individual.
Participants assigned to the intervention group will participated in a 16-week remote exercise intervention. Following a home/space environment and technology needs assessment, participants will attend a one-on-one orientation and practice class with a research assistant. Participants will join a live-streamed, instructor-led group Enhance Fitness exercise session for 1-hour, 3 days/week for 4 months (16-weeks).
PCT No. PCT/FI93/00086 Sec. 371 Date Sep. 12, 1994 Sec. 102(e) Date Sep. 12, 1994 PCT Filed Mar. 10, 1993 PCT Pub. No. WO93/17581 PCT Pub. Date Sep. 16, 1993A method for removing phenylalanine from proteinaceous compositions is disclosed wherein the protein contained in the proteinaceous composition is degraded enzymatically with a proteolytic enzyme into a protein hydrolysate. The protein hydrolysate thus obtained is treated with adsorption resin in a column that is eluted with water, the fraction wherefrom phenylalanine has been removed is recovered and salts are removed from the fraction thus recovered. Finally the recovered fraction is concentrated and dried. A palatable proteinaceous composition from which phenylalanine has been removed is also disclosed. This proteinaceous composition is used as a special nutrient preparation or a component of such in the diet of patients suffering from phenylketonuria.
Fifty two patients will be randomly divided into two groups i.e. Group-A (n=26) and B (n=26) respectively through simple random sampling, sealed envelope method. Informed consent will be taken from the participant prior to intervention. Baseline assessment will be carried out before the first session of all the recruited participants on four outcome measures using, Patrick's FABER test for provocation of pain, NPRS for intensity of pain, RMDQ for physical disability and PALM Pelvic Inclinometer for pelvic asymmetry respectively. Skin reaction test will be conducted before randomization after the baseline assessment for all participants. A small patch of kinesio tape will be applied to the hip region and the participants will be asked to keep it for 24 hours. If any of the participants will develop allergic reaction, it will be removed immediately and participants with positive results will be excluded from the study. After this test, the allergy-free patients will be randomized into 2 groups for treatment. Participants of Group-A will be applied KT with conventional physiotherapy while Group-B participants will perform MET with conventional physiotherapy. Whereas, both the groups will be given 12 sessions of their respective protocol, comprising 20 minutes, 3 times/week for the duration of 4 weeks. After the end of the intervention, subjects will be reassessed after the last session and data will be collected on the same outcome measures for further evaluation
Methylphenidate hydrochloride is a mild central nervous system (CNS) stimulant, available as 2.5 mg, 5 mg and 10 mg chewable tablets for oral administration. Methylphenidate hydrochloride is methyl α-phenyl-2-piperidineacetate hydrochloride, and its structural formula is

Methylphenidate hydrochloride USP is a white to off-white powder. Its solutions are acid to litmus. It is soluble in water, alcohol, and chloroform.

Each Methylphenidate Hydrochloride Chewable Tablet, for oral administration, contains 2.5 mg, 5 mg or 10 mg of methylphenidate hydrochloride USP. In addition, Methylphenidate Hydrochloride Chewable Tablets also contain the following inactive ingredients: aspartame, maltose, microcrystalline cellulose, grape flavor, pregelatinized starch, phosphoric acid, and stearic acid.
OBJECTIVES: I. Determine the maximum tolerated dose of raltitrexed when administered with fluorouracil in patients with advanced colorectal carcinoma. II. Determine the toxicity and safety of this regimen in these patients. III. Assess, in a preliminary manner, the antitumor activity of this regimen in these patients.

OUTLINE: This is a dose-escalation study of raltitrexed. Patients receive raltitrexed IV over 15 minutes followed 24 hours later by fluorouracil IV. Treatment continues every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of raltitrexed until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose immediately preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6-10 patients are treated at the MTD. Patients are followed for 6 weeks.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 5-20 months.
BACKGROUND: Biomechanical alterations in patients with low back pain (LBP), as reduced range of motion or strength, do not appear to be exclusively related to the trunk. Thus, studies have investigated biomechanical changes in the hip, due to the proximity of this joint to the low back region. However, the relationship between hip biomechanical changes in patients with LBP is still controversial and needs to be summarized. Therefore, the aim of this study was to systematically review observational studies that used biomechanical assessments in patients with non-specific LBP.
METHODS: The search for observational studies that evaluated hip biomechanical variables (i.e., range of motion, kinematic, strength, and electromyography) in adults with non-specific acute, subacute, and chronic LBP was performed in the PubMed, Embase, Cinahl and Sportdiscus databases on February 22nd, 2024. Four blocks of descriptors were used: 1) type of study, 2) LBP, 3) hip and 4) biomechanical assessment. Two independent assessors selected eligible studies and extracted the following data: author, year of publication, country, study objective, participant characteristics, outcomes, and results. The methodological quality of the studies was assessed using the Epidemiological Appraisal Instrument and classified as low, moderate, and high. Due to the heterogeneity of the biomechanical assessment and, consequently, of the results among eligible studies, a descriptive analysis was performed.
RESULTS: The search strategy returned 338 articles of which 54 were included: nine articles evaluating range of motion, 16 evaluating kinematic, four strength, seven electromyography and 18 evaluating more than one outcome. The studies presented moderate and high methodological quality. Patients with LBP, regardless of symptoms, showed a significant reduction in hip range of motion, especially hip internal rotation, reduction in the time to perform functional activities such as sit-to-stance-to-sit, sit-to-stand or walking, greater activation of the hamstrings and gluteus maximus muscles and weakness of the hip abductor and extensor muscles during specific tests and functional activities compared to healthy individuals.
CONCLUSION: Patients with LBP present changes in range of motion, task execution, activation, and hip muscle strength when compared to healthy individuals. Therefore, clinicians must pay greater attention to the assessment and management of the hip during the treatment of these patients.
SYSTEMATIC REVIEW REGISTRATION: International Prospective Register of Systematic Reviews (PROSPERO) (CRD42020213599).
Patients will be treated according to current practice as described in the guidelines of the European Society of Cardiology (ESC). For AF, this has been provided by Kirchhof et al. (2016 Eur Heart J). HF treatment will follow the 2016 ESC guideline for HF (Ponikowski et al., 2016 Eur Heart J), and TRH will be treated according to the ESC treatment guideline for arterial hypertension (Mancia et al., 2013 Eur Heart J).
Insulin exerts its actions not only on peripheral organs but is also transported into the brain where it performs distinct functions in various brain regions. This review highlights recent advancements in our understanding of insulin's actions within the brain, with a specific emphasis on investigations in humans. It summarises current knowledge on the transport of insulin into the brain. Subsequently, it showcases robust evidence demonstrating the existence and physiological consequences of brain insulin action, while also introducing the presence of brain insulin resistance in humans. This pathophysiological condition goes along with an impaired acute modulation of peripheral metabolism in response to brain insulin action, particularly in the postprandial state. Furthermore, brain insulin resistance has been associated with long-term adiposity and an unfavourable adipose tissue distribution, thus implicating it in the pathogenesis of subgroups of obesity and (pre)diabetes that are characterised by distinct patterns of body fat distribution. Encouragingly, emerging evidence suggests that brain insulin resistance could represent a treatable entity, thereby opening up novel therapeutic avenues to improve systemic metabolism and enhance brain functions, including cognition. The review closes with an outlook towards prospective research directions aimed at further elucidating the clinical implications of brain insulin resistance. It emphasises the critical need to establish feasible diagnostic measures and effective therapeutic interventions.
Leukopenia in the range of 1000 to <3000 WBC x 106/L occurred in 18% of patients with CTCL receiving an initial dose of 300 mg/m2/day of bexarotene. Patients receiving an initial dose greater than 300 mg/m2/day of bexarotene had an incidence of leukopenia of 43%. No patient with CTCL treated with bexarotene developed leukopenia of less than 1000 WBC x 106/L. The usual time to onset of leukopenia was four to eight weeks after initiating bexarotene. The leukopenia observed in most patients was predominately neutropenia. In the 300 mg/m2/day initial dose group, the incidence of NCI Grade 3 and Grade 4 neutropenia, respectively, was 12% and 4%. The leukopenia and neutropenia experienced during bexarotene therapy resolved after dose reduction or discontinuation of treatment, on average within 30 days in 93% of the patients with CTCL and 82% of patients with non-CTCL cancers. Leukopenia and neutropenia were rarely associated with severe sequelae or serious adverse events. Obtain complete blood counts (CBC) at baseline and periodically during treatment.
The invention discloses a compound oral preparation for treating helicobacter pylori (hp) infection. The preparation is prepared from proton pump depressor, tunica mucosa ventriculi protective agent, and antibiotic chemical compound. The proton pump depressor can be selected from one of omeprazole, esomeprazole, lansoprazole, pantoprazole, minolazole, rebeprazole,tenatoprazole, tainolazole, leminoprazole, their magnesium salts, or other metalsalt. The dose range of hydrion depressor is 10-40mg. the antibiotic chemical compound can be selected from two of beta-lactam antibiotics, macrolide antibiotics, or other antibacterial drugs. The dose range for Each antibacterial drug is 100-1000mg. the tunica mucosa ventriculi protective agent can be selected from bismuth agent, ulcerlmin, marzulene-s, prostanoid, terpenes derivant, aluminum magnesium carbonate, growth factor, antioxidant, dosmalfate, or sanodin with dose range of 50 mu g-1000mg. The invention has important effect in eradicating H.pylori with simple preparation method, convenient administration, and good conformability.
To investigate the clinical value of contrast-enhanced ultrasound in the prediction of hepatic encephalopathy (HE) in patients with hepatitis B cirrhosis after intrahepatic portal-systemic shunt via jugular vein. In this retrospective study, we collected data from 75 patients with hepatitis B, cirrhosis, and portal hypertension who underwent jugular intrahepatic portosystemic shunt from February 2019 to February 2022. The diagnostic instrument used was the TOSHIBA Aplio500 color Doppler ultrasound with contrast-enhanced ultrasound capabilities. The trial group comprised 20 patients with HE within 3 months postsurgery, while the control group (CG) included 55 patients without HE within the same postoperative period. All patients underwent various examinations before and within 48 hours after surgery, including observation of liver and spleen size and stent position, as well as assessment of blood flow direction in portal and hepatic veins. Subsequently, contrast-enhanced ultrasound was employed to examine and observe perfusion changes of contrast agents in hepatic veins, hepatic arteries, and portal veins (PV). Changes in PV pressure gradient, intrahepatic, and stent blood flow perfusion (BFP) were explored in both postoperative trials and CGs. The trial group exhibited higher BFP volume, PV pressure gradient difference, and percentage decrease compared to the CG. A weak positive correlation was observed between blood flow within the liver stent and PV pressure gradient difference, as well as the percentage decrease in PV pressure gradient. The correlation coefficient between blood flowing perfusion volume within the stent and the difference in PV pressure gradient was R = 0.415 (P = .000). The correlating coefficient between BFP amount within the stent and the percentage decrease in PV pressure gradient was R = 0.261 (P = .027). The area under the receiver operating characteristic curve for stent perfusion volume, difference in PV pressure gradient, and percentage decrease in PV pressure gradient was 0.691, 0.759, and 0.742, respectively. An increase in PV pressure gradient accelerates blood flow within the stent, predisposing to HE. Changes in hepatic BFP following transjugular intrahepatic portosystemic shunt can effectively predict the occurrence of HE, demonstrating significant clinical relevance.
FIELD: cosmetology. SUBSTANCE: the suggested preparation contains a biologically active additive of plant and/or animal origin and a surface-active substance in cosmetically appropriate medium. Moreover, it additionally contains, at least, one cosmetically appropriate bisphosphate component. Components should be taken in a certain quantitative ratio. The preparation prevents hair fallout, improves the structure of dry and friable hair by making them to be shiny and healthy. EFFECT: higher efficiency of hair care. 14 cl
Participants in the control group will participate in the 12 Control/non-digital stimulation sessions of 45 minutes taking place twice a week for 6 weeks, in groups of 6 participants instead of the LUMEEN Virtual Reality sessions. The content of these sessions is described in the Intervention Description part of this document.
PURPOSE: A skin whitening composition containing, as an active ingredient, machilin-A obtained from Machilus thunbergii is provided. The composition has excellent stability, is safely applied to the skin without adverse effect and has excellent pigmentation-inhibiting effect by suppressing the formation of melamine. CONSTITUTION: The skin whitening composition contains 0.000001 to 10% by weight of machilin-A represented by the formula(1), based on the total weight of the composition. The machilin-A is obtained by extracting machilin-A in a solvent selected from the group consisting of C1-4 lower alcohol, ethyl acetate, acetone, ether, benzene, chloroform, hexane, cyclohexane and petroleum ether. The composition is formulated into any one selected from the group consisting of skin lotion, cream, foundation, essence, gel, a mask pack, cleansing, soap and an ointment. The composition is effective for skin whitening or improvement of chloasma or freckles.
Patients receive nivolumab IV over 30 minutes on day, ipilimumab IV over 30 minutes on day 1, and camu camu PO QD continuously with each cycle. Cycles repeat every 3 weeks for cycles 1-4. Beginning cycle 5, patients receive nivolumab over 30 minutes on day 1, and camu camu PO QD of each cycle. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and stool sample collection and undergo CT and/or bone scan and/or MRI on trial.